{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.836","value":"1.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"One 4-week cycle of blinatumomab 15 μg/m\\^2/day as a continuous intravenous infusion (CIVI).","id":"OG000","title":"Blinatumomab"}],"paramType":"MEAN","populationDescription":"PK Analysis Set: participants who received any infusion of blinatumomab and had at least one PK sample collected.","reportingStatus":"POSTED","timeFrame":"Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15","title":"Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)","type":"SECONDARY","unitOfMeasure":"L/hr/m^2"}